E

Looking for Signals in Cancer Immunometabolism

In this post we’re taking a look at what we learnt about immunometabolism at AACR20 and some of the early signals from a cancer new product development perspective.

August 6, 2020
E

A Journey into Immunometabolism and its Potential for Cancer Immunotherapy

The aim of this post is to give you a sense of the potential of immunometabolism to impact T cell fate, fitness, and function.

August 4, 2020
E

What’s the skinny on a new IO target in oncology R&D?

A new emerging IO target of interest caught out attention, now what?

July 28, 2020
E

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020
E

The magic of making proteins disappear

In our latest company interview we continue our ongoing AACR series on various protein degraders and how…

July 21, 2020
E

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020
E

Putting NK cells to work

Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...

July 7, 2020
E

Are gamma delta T cells ready yet for prime time?

Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?

July 1, 2020
E

Will a novel way to target IL–18 be a winner?

Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?

June 29, 2020
E

Looking through the window at some novel new product development concepts in oncology

A look at some novel and promising approaches in early oncology new product development

June 24, 2020
E

How the immune response to cancer can be shaped by the nature of the cancer cells

Looking under the hood in NSCLC at underlying mutations and whether or not they impact survival

June 23, 2020
E

A rock around the breast cancer clock

Highlights from various breast cancer trials and new pipeline developments

June 2, 2020
E

Can we add fire to the immune system with TIGIT?

A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer

June 1, 2020
E

Will the next generation SERDs make an impact in ER+ HER2- breast cancer?

An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer

May 21, 2020
E

ASCO20 Preview on the importance of modality in oncology R&D

Does modality matter in oncology drug development and if so, where?

May 19, 2020
E

Putting some colour on the TIGIT niche

A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.

May 12, 2020
E

New directions in adenosine axis targeting

A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview

May 7, 2020
E

Flying high in the DDR oncology niche

New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.

May 5, 2020
E

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020
E

Standing out from the crowd

One particular presentation stood out from the others at AACR20 this year

April 29, 2020
E

Postcard 2 on Adoptive Cell Therapies from the AACR20 Virtual Meeting

In our latest postcard from AACR20 virtual meeting we take a look at the adoptive cell therapy plenary session

April 28, 2020
E

Postcards from Day 1 of AACR20

Commentary on Day 1 of the AACR20 Virtual Meeting

April 28, 2020
E

One swallow does not a summer make

Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20

April 27, 2020
E

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020
E

Reflections on new developments in the KRAS niche

Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2

April 20, 2020
E

AACR Preview 2 – Pathways to Success in Targeted Therapies

A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies

April 16, 2020
E

Every cloud has a silver lining

What to watch out for at AACR20 - the first of our meeting previews is here!

April 15, 2020
E

Impact of Covid–19 on Cancer Conferences

A look at the revised schedule and timelines for upcoming Spring cancer conference season

April 13, 2020
E

Time is ticking on the bromodomain landscape

Where are they now four years on? A look at the BET/Bromodomain landscape

April 3, 2020
E

Exploring the immunological links between lung cancer and Covid–19

Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?

March 31, 2020
E

When oncology and coronavirus worlds collide

Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus

March 4, 2020